Breast Cancer Research and Treatment

, Volume 151, Issue 2, pp 465–474 | Cite as

Comparison of breast cancer risk in women with and without systemic lupus erythematosus in a Medicare population

  • Waseem Khaliq
  • Rehan Qayyum
  • Jeffrey Clough
  • Dhananjay Vaidya
  • Antonio C. Wolff
  • Diane M. Becker


Studies have suggested a decreased breast cancer risk in women with systemic lupus erythematosus. However, these studies enrolled younger patients identified primarily from lupus clinics. We compared the 5-year incidence of breast cancer among women with and without a diagnosis of SLE in a large population-based study of Medicare beneficiaries. We used a 20 % sample to create a cohort of 3,670,138 women from 2006 Medicare claims data with and without SLE at baseline. The study had 80 % power to detect whether the 5-year breast cancer incidence in the SLE cohort was 13 % higher or lower than the non-SLE cohort. Of the 18,423 women with SLE, 21 % were African American and 53 % were ≥65 years. The absolute age-adjusted risk for breast cancer in women with SLE was 2.23 (95 % CI 1.94–2.55) and 2.14 (95 % CI 1.96–2.34) in controls per 100 women. The overall absolute age and race adjusted incidence rate was 1.04 (95 % CI 0.90–1.21). Among women with SLE from “Others” (Hispanic, Native American, and/or Asian), the age-adjusted risk for breast cancer was 2.44 per 100 women (95 % CI 1.07–2.18), and age-adjusted incidence rate was 1.52 (95 % CI 1.07–2.18). In contrast to prior clinic-based studies, this population-based cohort study showed that the risk of breast cancer in women with SLE was not lower than in women without SLE. Women with SLE should follow routine breast cancer screening recommendations for their age group to avoid delay in diagnosis, because the presence of SLE may affect selection of early breast cancer therapies.


Systemic lupus erythematosus Breast cancer risk Medicare claims data 



Sponsored in part by the Harvey research fund of the Johns Hopkins University School of Medicine, Department of Medicine.

Conflict of interest

All authors have no conflict of interest.

Financial support and disclosure

No Competing financial interests exist.


  1. 1.
    Ward MM (2004) Prevalence of physician-diagnosed systemic lupus erythematosus in the United States: results from the third national health and nutrition examination survey. J Womens Health 13:713–718CrossRefGoogle Scholar
  2. 2.
    Helmick CG, Felson DT, Lawrence RC et al (2008) National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: part I. Arthr Rheum 58:15–251CrossRefGoogle Scholar
  3. 3.
    Doria A, Iaccarino L, Ghirardello A et al (2006) Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med 119:700–706CrossRefPubMedGoogle Scholar
  4. 4.
    Bernatsky S, Boivin JF, Joseph L et al (2006) Mortality in systemic lupus erythematosus. Arthr Rheum 54:2550–2557CrossRefGoogle Scholar
  5. 5.
    Parikh-Patel A, White RH, Allen M, Cress R (2008) Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California. Cancer Causes Control 19:887–894CrossRefPubMedCentralPubMedGoogle Scholar
  6. 6.
    Bernatsky S, Boivin JF, Joseph L et al (2005) An international cohort study of cancer in systemic lupus erythematosus. Arthr Rheum 52:1481–1490CrossRefGoogle Scholar
  7. 7.
    Cibere J, Sibley J, Haga M (2001) Systemic lupus erythematosus and the risk of malignancy. Lupus 10:394–400CrossRefPubMedGoogle Scholar
  8. 8.
    Chen YJ, Chang YT, Wang CB, Wu CY (2010) Malignancy in systemic lupus erythematosus: a nationwide cohort study in Taiwan. Am J Med 123:1150.e1–1150.e6PubMedGoogle Scholar
  9. 9.
    Bernatsky S, Ramsey-Goldman R, Labrecque J et al (2013) Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun 42:130–135CrossRefPubMedCentralPubMedGoogle Scholar
  10. 10.
    Kontos M, Fentiman IS (2008) Systemic lupus erythematosus and breast cancer. Breast J 14:81–86CrossRefPubMedGoogle Scholar
  11. 11.
    Bjornadal L, Lofstrom B, Yin L, Lundberg I, Ekbom A (2002) Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus. Scand J Rheumatol 31:66–71CrossRefPubMedGoogle Scholar
  12. 12.
    Bernatsky SR, Clarke AE, Petri MA et al (2010) Further defining cancer risk in systemic lupus: updated results in an expanded international multi-centre cohort [abstract]. Arthr Rheum 62:731Google Scholar
  13. 13.
    Bernatsky S, Ramsey-Goldman R, Foulkes WD, Gordon C, Clarke AE (2011) Breast, ovarian, and endometrial malignancies in systemic lupus erythematosus: a meta-analysis. Br J Cancer 104:1478–1481CrossRefPubMedCentralPubMedGoogle Scholar
  14. 14.
    Dey D, Kenu E, Isenberg DA (2013) Cancer complicating systemic lupus erythematosus: a dichotomy emerging from a nested case-control study. Lupus 22:919–927CrossRefPubMedCentralPubMedGoogle Scholar
  15. 15.
    Ramsey-Goldman R, Mattai SA, Schilling E et al (1998) Increased risk of malignancy in patients with systemic lupus erythematosus. J Investig Med 46:217–222PubMedGoogle Scholar
  16. 16.
    Pettersson T, Pukkala E, Teppo L, Friman C (1992) Increased risk of cancer in patients with systemic lupus erythematosus. Ann Rheum Dis 51:437–439CrossRefPubMedCentralPubMedGoogle Scholar
  17. 17.
    Sweeney DM, Manzi S, Janosky J et al (1995) Risk of malignancy in women with SLE. J Rheumatol 22:1478–1482PubMedGoogle Scholar
  18. 18.
    Abu-Shakra M, Gladman DD, Urowitz MB (1996) Malignancy in systemic lupus erythematosus. Arthr Rheum 39:1050–1054CrossRefGoogle Scholar
  19. 19.
    Mellemkjaer L, Andersen V, Linet MS et al (1997) Non-Hodgkin’s lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthr Rheum 40:761–768CrossRefGoogle Scholar
  20. 20.
    Sultan SM, Ioannou Y, Isenberg DA (2000) Is there an association of malignancy with systemic lupus erythematosus? An analysis of 276 patients under long-term review. Rheumatology 39:1147–1152CrossRefPubMedGoogle Scholar
  21. 21.
    Dupla ML, Khamashta M, Garcia VP et al (1993) Malignancy in systemic lupus erythematosus: a report of five cases in a series of 96 patients. Lupus 2:377–380CrossRefGoogle Scholar
  22. 22.
  23. 23.
    Katz JN, Barrett J, Liang MH et al (1997) Sensitivity and positive predictive value of Medicare part B physician claims for rheumatologic diagnoses and procedures. Arthr Rheum. 40:1594–1600CrossRefGoogle Scholar
  24. 24.
    Cooper GS, Yuan Z, Stange KC, Dennis LK, Amini SB, Rimm AA (1999) The sensitivity of Medicare claims data for case ascertainment of six common. Med Care 37(5):436–444CrossRefPubMedGoogle Scholar
  25. 25.
    TessierCloutier B, Clarke AE, Ramsey-Goldman R et al (2013) Breast cancer in systemic lupus erythematosus. Oncology 85(2):117–121CrossRefGoogle Scholar
  26. 26.
    Cooper GS, Dooley MA, Treadwell EL, St Clair EW, Gilkeson GS (2002) Hormonal and reproductive risk factors for development of systemic lupus erythematosus: results of a population-based, case: control study. Arthr Rheum 46:1830–1839CrossRefGoogle Scholar
  27. 27.
    Rahim R, Strobl JS (2009) Hydroxychloroquine, chloroquine, and all-trans retinoic acid regulate growth, survival, and histone acetylation in breast cancer cells. Anticancer Drugs 20:736–745CrossRefPubMedGoogle Scholar
  28. 28.
    King J, Costenbader K (2007) Characteristics of patients with systemic lupus erythematosus (SLE) and non-Hodgkins lymphoma (NHL). Clin Rheumatol 26:1491–1494CrossRefPubMedGoogle Scholar
  29. 29.
    Bernatsky S, Boivin JF, Gordon C et al (2008) The relationship between cancer and medication exposure in SLE. Ann Rheum Dis 67:74–79CrossRefPubMedGoogle Scholar
  30. 30.
    Kang KY, Kim HO, Yoon HS, Lee J, Lee WC, Ko HJ, Ju JH, Cho CS, Kim HY, Park SH (2010) Incidence of cancer among female patients with systemic lupus erythematosus in Korea. Clin Rheumatol 29:381–388Google Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Waseem Khaliq
    • 1
  • Rehan Qayyum
    • 1
  • Jeffrey Clough
    • 1
  • Dhananjay Vaidya
    • 1
  • Antonio C. Wolff
    • 2
  • Diane M. Becker
    • 1
  1. 1.Department of MedicineJohns Hopkins University School of MedicineBaltimoreUSA
  2. 2.The Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsBaltimoreUSA

Personalised recommendations